<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920773</url>
  </required_header>
  <id_info>
    <org_study_id>NMP/CARE/01</org_study_id>
    <nct_id>NCT04920773</nct_id>
  </id_info>
  <brief_title>Community-based Post-exposure Prophylaxis for COVID-19</brief_title>
  <official_title>Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NMP Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarogyam UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samta Ayurveda Prakoshtha, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Padmanabhama Ayurveda Hospital and Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NMP Medical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specifically identified Ayurvedic preparations is recommended by ministry of AYUSH as&#xD;
      post-exposure prophylaxis to efficaciously prevent a negative person who has come into&#xD;
      contact with COVID-19-positive. Traditionally, recommended Ayurvedic preparations have been&#xD;
      used as antioxidants, antimicrobial and anti-inflammatory properties. Particularly, Guduchi&#xD;
      Ghanvati has been recognised with its ability to control viral attachment, viral replication&#xD;
      and induce immune response in pre clinical settings, and found to be one among the most&#xD;
      important drugs in Ayurveda to fight against COVID-19.&#xD;
&#xD;
      However, known gap in guideline implementation and its impact on preventing active infection&#xD;
      in exposed cases is unclear. Study aimed to increase the use of recommended AYUSH guidelines&#xD;
      by having registered AYUSH physicians provide these medications, when indicated, in community&#xD;
      based participants after known exposure to the SARS-CoV-2 coronavirus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Actual">June 6, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with active COVID-19</measure>
    <time_frame>14-days following exposure</time_frame>
    <description>PCR- proven COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to symptoms onset</measure>
    <time_frame>14-days</time_frame>
    <description>Days until start of symptoms of COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity</measure>
    <time_frame>14 days</time_frame>
    <description>Visual Analog Scale of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ayurveda Care Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Guduchi Ghanvati</intervention_name>
    <description>500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily</description>
    <arm_group_label>Ayurveda Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard guidelines</intervention_name>
    <description>Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask</description>
    <arm_group_label>Ayurveda Care Group</arm_group_label>
    <arm_group_label>Usual Care Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women 18 to 60 years of age&#xD;
&#xD;
          -  Household contact residing with the index case in the 14 days prior to index diagnosis&#xD;
             within a residence without maintaining social distance&#xD;
&#xD;
          -  Access to device and internet for telephonic appointments and follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently hospitalised&#xD;
&#xD;
          -  Symptomatic with fever, cough, or shortness of breath&#xD;
&#xD;
          -  Use of anti-malarial treatment or chemoprophylaxis&#xD;
&#xD;
          -  Moderately or Severely ill for any co-morbid condition requiring medical assistance.&#xD;
&#xD;
          -  Cognitive impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Sharma</last_name>
    <role>Study Chair</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Skanthesh Lakshmanan</last_name>
    <role>Study Chair</role>
    <affiliation>Niramaya clinic, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isha Goyal</last_name>
    <role>Principal Investigator</role>
    <affiliation>NMP Medical Research Institute, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abijith Venu</last_name>
    <role>Study Chair</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahil Singhal</last_name>
    <role>Study Director</role>
    <affiliation>NMP Medical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhimanyu Kumar</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NMP Medical Research Institute</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Padmnabham Ayurveda Hospital &amp; Research Center</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post Exposure Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

